Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial

被引：0

作者：

Kagawa, Tatehiro ^{[1
]}

Kojima, Sei-ichiro ^{[2
]}

Shiraishi, Koichi ^{[1
]}

Hirose, Shunji ^{[1
]}

Arase, Yoshitaka ^{[1
]}

Takashimizu, Shinji ^{[2
]}

Watanabe, Norihito ^{[2
]}

Nagata, Naruhiko ^{[3
]}

Numata, Makoto ^{[3
]}

Shiozawa, Hirokazu ^{[4
]}

Nishizaki, Yasuhiro ^{[4
]}

Toki, Mayu ^{[5
]}

Sugita, Teruji ^{[5
]}

Nomura, Kijuro ^{[6
]}

Sakaguchi, Takashi ^{[7
]}

Atsukawa, Kazuhiro ^{[7
]}

Tajima, Hiroto ^{[8
]}

Tei, Yoshihiro ^{[8
]}

Inomoto, Tsutomu ^{[9
]}

Mine, Tetsuya ^{[1
]}

机构：

[1] Tokai Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Isehara, Kanagawa 2591193, Japan

[2] Tokai Univ, Hachioji Hosp, Dept Internal Med, Div Gastroenterol, Hachioji, Tokyo, Japan

[3] Tokai Univ, Oiso Hosp, Dept Internal Med, Div Gastroenterol, Nakagun, Japan

[4] Tokai Univ, Tokyo Hosp, Dept Internal Med, Div Gastroenterol, Tokyo 151, Japan

[5] Yamachika Mem Hosp, Odawara, Japan

[6] Nomura Shokakinaika, Chigasaki, Kanagawa, Japan

[7] Hiratsuka City Hosp, Hiratsuka, Kanagawa, Japan

[8] Japan Med Alliance Ebina Gen Hosp, Ebina, Kanagawa, Japan

[9] Yugawara Kosei Nenkin Hosp, Ashigarashimogun, Japan

来源：

HEPATOLOGY RESEARCH | 2013年 / 43卷 / 09期

关键词：

adjuvant; chronic hepatitis C; cyclooxygenase-2; inhibitor; interferon; meloxicam; neutropenia; NONSTEROIDAL ANTIINFLAMMATORY DRUG; PEGYLATED-INTERFERON-ALPHA; VIROLOGICAL RESPONSE; VIRUS-INFECTION; PLUS RIBAVIRIN; THERAPY; COMBINATION; KETOPROFEN; CYCLOOXYGENASE-2; TELAPREVIR;

D O I：

10.1111/hepr.12046

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim: In this multicenter, randomized trial, we evaluated the effectiveness of meloxicam - a non-steroidal anti-inflammatory drug - as an adjuvant for enhancing antiviral efficacy and preventing neutropenia during the treatment of patients with genotype 1 chronic hepatitis C using peginterferon and ribavirin. Methods: A total of 60 patients were randomly assigned, in a 1:1 ratio, to either the meloxicam or the control group after stratification by neutrophil count. Both groups received weekly peginterferon-alpha-2a (180g) and a weight-based dose of ribavirin for 48 weeks. The meloxicam group received meloxicam (10mg/day) for the first 8 weeks after initiation of treatment. Results: Through intent-to-treat analysis, we found that the sustained virological response rate in the meloxicam group (19/30, 63.3%) was significantly higher than in the control group (11/30, 36.7%, P<0.05). The relapse rate was more than twice as high (45%) in the control group than in the meloxicam group (19.0%); however, this difference was not statistically significant. The rate of neutrophil decrease, calculated by dividing the lowest value observed during the first 8 weeks by pretreatment count, was significantly smaller in the meloxicam group (55.1 +/- 14.3%) than in the control group (62.3 +/- 9.6%, P<0.05). Conclusion: Meloxicam enhanced antiviral efficacy and reduced the decline in neutrophil counts for the peginterferon and ribavirin treatment of genotype 1 chronic hepatitis C. This drug could be a reasonable adjuvant for the treatment of patients with chronic hepatitis C. The present study including a small number of patients warrants larger clinical trials.

引用

页码：925 / 932

页数：8

共 26 条

[21] IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy [J].

Suppiah, Vijayaprakash ;

Moldovan, Max ;

Ahlenstiel, Golo ;

Berg, Thomas ;

Weltman, Martin ;

Abate, Maria Lorena ;

Bassendine, Margaret ;

Spengler, Ulrich ;

Dore, Gregory J. ;

Powell, Elizabeth ;

Riordan, Stephen ;

Sheridan, David ;

Smedile, Antonina ;

Fragomeli, Vincenzo ;

Mueller, Tobias ;

Bahlo, Melanie ;

Stewart, Graeme J. ;

Booth, David R. ;

George, Jacob .

NATURE GENETICS, 2009, 41 (10) :1100-U74

[22]

TANAKA T, 1994, HEPATOLOGY, V19, P1347, DOI 10.1002/hep.1840190605

[23] Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C [J].

Tanaka, Yasuhito ;

Nishida, Nao ;

Sugiyama, Masaya ;

Kurosaki, Masayuki ;

Matsuura, Kentaro ;

Sakamoto, Naoya ;

Nakagawa, Mina ;

Korenaga, Masaaki ;

Hino, Keisuke ;

Hige, Shuhei ;

Ito, Yoshito ;

Mita, Eiji ;

Tanaka, Eiji ;

Mochida, Satoshi ;

Murawaki, Yoshikazu ;

Honda, Masao ;

Sakai, Akito ;

Hiasa, Yoichi ;

Nishiguchi, Shuhei ;

Koike, Asako ;

Sakaida, Isao ;

Imamura, Masatoshi ;

Ito, Kiyoaki ;

Yano, Koji ;

Masaki, Naohiko ;

Sugauchi, Fuminaka ;

Izumi, Namiki ;

Tokunaga, Katsushi ;

Mizokami, Masashi .

NATURE GENETICS, 2009, 41 (10) :1105-U81

[24] Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways [J].

Trujillo-Murillo, Karina ;

Rincon-Sanchez, Ana Rosa ;

Martinez-Rodriguez, Herminia ;

Bosques-Padilla, Francisco ;

Ramos-Jimenez, Javier ;

Barrera-Saldana, Hugo A. ;

Rojkind, Marcos ;

Rivas-Estilla, Ana Maria .

HEPATOLOGY, 2008, 47 (05) :1462-1472

[25] Virological response in patients with hepatitis C virus genotype 1b and a high viral load -: Impact of peginterferon-α-2a plus ribavirin dose reductions and host-related factors [J].

Yamada, Gotaro ;

Iino, Shiro ;

Okuno, Tadao ;

Omata, Masao ;

Kiyosawa, Kendo ;

Kumada, Hiromitsu ;

Hayashi, Norio ;

Sakai, Takahiro .

CLINICAL DRUG INVESTIGATION, 2008, 28 (01) :9-16

[26] Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon [J].

Zarski, JP ;

Maynard-Muet, M ;

Chousterman, S ;

Baud, M ;

Barnoud, R ;

Abergel, A ;

Bacq, Y ;

Combis, JM ;

Causse, X ;

Tran, A ;

Oberti, F ;

Minello, A ;

Bresson-Hadni, S ;

Bailly, F ;

Raabe, JJ ;

Leroy, V ;

Hamici, L ;

Hicham, T ;

Girardin, MFS .

HEPATOLOGY, 1998, 27 (03) :862-867

← 1 2 3 →